Shares of Roivant Sciences Ltd. (NASDAQ:ROIV – Get Free Report) have received a consensus rating of “Moderate Buy” from the ten brokerages that are presently covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a hold recommendation and nine have issued a buy recommendation on the company. The average 1-year target price among brokerages that have issued a report on the stock in the last year is $16.50.
A number of analysts have weighed in on the company. Piper Sandler began coverage on Roivant Sciences in a research note on Friday, January 5th. They issued an “overweight” rating and a $20.00 price target on the stock. HC Wainwright decreased their target price on Roivant Sciences from $18.00 to $17.00 and set a “buy” rating for the company in a research note on Wednesday, February 14th. Wolfe Research started coverage on Roivant Sciences in a report on Thursday, February 15th. They issued an “outperform” rating and a $17.00 price target for the company. Guggenheim cut their price objective on shares of Roivant Sciences from $17.00 to $16.00 and set a “buy” rating on the stock in a report on Wednesday, November 15th. Finally, Bank of America upped their target price on shares of Roivant Sciences from $11.00 to $12.00 and gave the company a “neutral” rating in a report on Tuesday, January 2nd.
Get Our Latest Report on Roivant Sciences
Insider Buying and Selling
Hedge Funds Weigh In On Roivant Sciences
A number of institutional investors have recently bought and sold shares of ROIV. Vanguard Group Inc. lifted its holdings in shares of Roivant Sciences by 26.3% during the 4th quarter. Vanguard Group Inc. now owns 7,075,651 shares of the company’s stock valued at $79,460,000 after buying an additional 1,473,085 shares during the last quarter. Virtu Financial LLC acquired a new stake in Roivant Sciences in the 4th quarter worth approximately $136,000. Price T Rowe Associates Inc. MD lifted its holdings in shares of Roivant Sciences by 2.0% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 3,786,613 shares of the company’s stock worth $42,524,000 after buying an additional 74,131 shares during the last quarter. Public Employees Retirement System of Ohio lifted its holdings in shares of Roivant Sciences by 5.3% during the fourth quarter. Public Employees Retirement System of Ohio now owns 149,031 shares of the company’s stock worth $1,674,000 after buying an additional 7,459 shares during the last quarter. Finally, Dagco Inc. acquired a new position in shares of Roivant Sciences during the fourth quarter worth approximately $27,000. Hedge funds and other institutional investors own 64.76% of the company’s stock.
Roivant Sciences Stock Down 2.2 %
ROIV stock opened at $10.44 on Friday. The company’s 50 day moving average price is $10.95 and its 200 day moving average price is $10.49. The firm has a market capitalization of $8.41 billion, a price-to-earnings ratio of 2.01 and a beta of 1.37. Roivant Sciences has a fifty-two week low of $6.59 and a fifty-two week high of $13.24. The company has a debt-to-equity ratio of 0.06, a quick ratio of 27.79 and a current ratio of 27.79.
Roivant Sciences (NASDAQ:ROIV – Get Free Report) last announced its quarterly earnings data on Tuesday, February 13th. The company reported ($0.26) EPS for the quarter, beating analysts’ consensus estimates of ($0.33) by $0.07. The company had revenue of $37.14 million for the quarter, compared to the consensus estimate of $30.72 million. Roivant Sciences had a net margin of 3,624.14% and a negative return on equity of 33.38%. On average, equities research analysts anticipate that Roivant Sciences will post -1.36 EPS for the current fiscal year.
About Roivant Sciences
Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.
Further Reading
- Five stocks we like better than Roivant Sciences
- ESG Stocks, What Investors Should Know
- Unbearably Good Investment: A Build-A-Bear Stock Analysis
- 3 Ways To Invest In Coffee, Other Than Drinking It
- Coinbase Stock Tempting but isn’t without its Risks
- Upcoming IPO Stock Lockup Period, Explained
- This Industrial Products Stock is Goldman’s Favorite This Cycle
Receive News & Ratings for Roivant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roivant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.